Pipeline

Sorrento’s R&D is focused on driving innovation in cancer treatment, full pain control, autoimmune and COVID-19

Portfolio Key Programs Indication Preclinical Phase I Phase II Phase III/Pivotal FDA Approval
Immuno-Oncology

 

CD38 CAR-T Multiple Myeloma

30%*

CD38 DAR-T Multiple Myeloma

10%*

CD38 ADC Amyloidosis

30%*

Seprehvir™ Solid Tumors

30%*

Pain

RTX (resiniferatoxin)
Epidural route
Terminal Cancer Pain

55%*

Orphan designation

RTX (resiniferatoxin)
Intra-articular route
Moderate to Severe OA

55%*

RTX (resiniferatoxin)
Intra-articular route
TKR Deferment

10%*

Pending designation
Lymphatic Delivery

Sofusa® anti-TNF Autoimmune

10%*

Sofusa® anti-PD-1 CTCL

10%*

COVID-19 Programs

COVI-GUARD Antibody

10%*

COVI-SHIELD Antibody Cocktail

10%*

COVIDTRAP ACE2 Receptor Decoy

10%*

Immuno-Oncology
Key Programs (Indication) Phase
CD38 CAR-T (Multiple Myeloma) Ph I
CD38 DAR-T (Multiple Myeloma) Preclinical
CD38 ADC (Amyloidosis) Ph I
Seprehvir™ (Solid Tumors) Ph I
Pain
Key Programs (Indication) Phase
RTX (resiniferatoxin) Epidural route (Terminal Cancer Pain) Ph II
RTX (resiniferatoxin) Intra-articular route (Moderate to Severe OA) Ph II
RTX (resiniferatoxin) Intra-articular route (TKR Deferment) Preclinical
Lymphatic Delivery
Key Programs (Indication) Phase
Sofusa® anti-TNF (Autoimmune) Preclinical
Sofusa® anti-PD-1 (Immuno Oncology) Preclinical
COVID-19 Programs
Key Programs (Indication) Phase
COVI-GUARD Preclinical
COVI-SHIELD Preclinical
COVIDTRAP Preclinical